论文部分内容阅读
目的探讨早产新生儿尿中α1微球蛋白(α1-MG)水平与早产儿疾病危重程度的关系。方法采用免疫比浊法测定86例生后24 h之内的早产新生儿(胎龄28～37周)尿中α1-MG含量,采用新生儿急性生理学评分标准(SNAP)评估患儿疾病危重程度,并分析尿α1-MG含量与新生儿急性生理学评分(SNAP)的关系。结果 86例早产新生儿的尿α1-MG含量与其胎龄及出生体重呈负相关关系(P值均<0.05),与SNAP分值呈正相关关系(P值<0.05)。结论尿α1-MG测定作为一种简捷快速、无损伤的临床实验室检测指标,其含量水平随着肾功能的逐渐发育成熟而降低,并随早产儿疾病危重程度的加重而增高,尿α1-MG含量对于早产儿病情危重程度的评估有良好的应用价值。
Objective To investigate the relationship between α1-microglobulin (α1-MG) in urine of premature neonates and the severity of premature infants. Methods Urinary α1-MG levels in 86 preterm infants (gestational age 28-37 weeks) within 24 hours after birth were measured by immunoturbidimetry. The severity of disease was evaluated using the Neonatal Acute Physiology Score (SNAP) , And analyzed the relationship between urinary α1-MG content and neonatal acute physiology score (SNAP). Results There was a negative correlation between urinary α1-MG content and gestational age and birth weight (P <0.05), and positively correlated with SNAP score (P <0.05). Conclusions Urinary α1-MG assay is a simple, rapid and nondestructive clinical laboratory test. The level of urinary α1-MG decreases with the gradual maturation of renal function and increases with the severity of preterm infants. Urinary α1- MG content for the assessment of the severity of preterm children have a good value.